This result in our study is consistent with that of the MAMMOTH study, a retrospective study of patients with MM refractory to anti-CD38 MoAbs that showed limited efficacy of elotuzumab-based treatment in anti-CD38 MoAb-refractory MM patients [11]. Here, CD38 is linked to Miyoshi myopathy.